Abstract
Improving the means of drug delivery has become an important field of pharmaceutical research. The development of safe and advanced vectors for gene therapy and other novel therapies will allow for targeted delivery of pharmaceutically active agents and carries promise to improve therapies both through increased efficiency (e.g. improved cellular uptake of the active drug) as well as lower toxicity (e.g. through targeted delivery only to the cells requiring treatment) for a large number of pharmaceutical agents. Here we are reviewing the nascent field using live bacteria as vectors for therapeutic and preventive agents in a wide range of areas, from vaccine purposes to gene therapy and delivery of therapeutic RNA interference. This review focuses particularly on the use of E. coli derived strains for therapeutic delivery.
Keywords: Bacterial delivery, invasin, listeriolysin, attenuation, FDA, gene transfer, RNAi, transkingdom RNAi, tkRNAi, dapA
Current Gene Therapy
Title: Engineered E. coli as Vehicles for Targeted Therapeutics
Volume: 10 Issue: 1
Author(s): Caitlin Buttaro and Johannes H. Fruehauf
Affiliation:
Keywords: Bacterial delivery, invasin, listeriolysin, attenuation, FDA, gene transfer, RNAi, transkingdom RNAi, tkRNAi, dapA
Abstract: Improving the means of drug delivery has become an important field of pharmaceutical research. The development of safe and advanced vectors for gene therapy and other novel therapies will allow for targeted delivery of pharmaceutically active agents and carries promise to improve therapies both through increased efficiency (e.g. improved cellular uptake of the active drug) as well as lower toxicity (e.g. through targeted delivery only to the cells requiring treatment) for a large number of pharmaceutical agents. Here we are reviewing the nascent field using live bacteria as vectors for therapeutic and preventive agents in a wide range of areas, from vaccine purposes to gene therapy and delivery of therapeutic RNA interference. This review focuses particularly on the use of E. coli derived strains for therapeutic delivery.
Export Options
About this article
Cite this article as:
Buttaro Caitlin and Fruehauf H. Johannes, Engineered E. coli as Vehicles for Targeted Therapeutics, Current Gene Therapy 2010; 10 (1) . https://dx.doi.org/10.2174/156652310790945593
DOI https://dx.doi.org/10.2174/156652310790945593 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs Liposome-Encapsulated Photosensitizers Against Bacteria
Recent Patents on Anti-Infective Drug Discovery Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Heat Shock Protein 90 – a Potential Target in the Treatment of Human Acute Myelogenous Leukemia
Current Cancer Drug Targets NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Stereoselective Pharmacodynamics and Pharmacokinetics of Proton Pump Inhibitors
Current Drug Metabolism TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry New, Substituted Derivatives of Dicarboximides and their Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Recent Development in Applications of Important Biopolymer Chitosan in Biomedicine, Pharmaceuticals and Personal Care Products
Current Tissue Engineering (Discontinued)